• PDF / 169,611 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 90 Downloads / 154 Views

DOWNLOAD

REPORT

---

1 S

Development of resistance to infliximab and lack of efficacy: case report A 56–year-old man developed resistance during treatment with infliximab for ulcerative colitis. Additionally, he exhibited lack of efficacy during treatment with mesalazine and unspecified corticosteroids for ulcerative colitis.* The man was diagnosed with left colitis in April 2017. Thereafter, he was referred to gastroenterology department, with rectal bleeding and colonoscopy revealed a proctosigmoiditis in active phase. Thus, he started treatment with oral unspecified corticosteroids [corticoids] and mesalazine [5- ASA] without any improvement (lack of efficacy). In May 2018, azathioprine was added, without a significant change. Then, in December 2018, infliximab was started that slightly improved the symptoms [dosages not stated, not all routes stated]. However, in May 2019, he exhibited lack of response to infliximab as total antibodies against infliximab were dosed, showing a 10 times higher concentration (drug resistance) along with decreased haemoglobin of 2 g/dL. Thus, treatment of his refractory ulcerative colitis was switched to adalimumab therapy. At present, the man’s status had improved, without any bleeding. * Reporter country was not stated. Timofte O, et al. Refractory left colitis treated with adalimumab (hyrimoz)-a case report. Journal of Gastrointestinal and Liver Diseases 28 (Suppl. 3): 17 abstr. 40, Sep 2019. 803497571 Available from: URL: https://www.jgld.ro/jgld/public/public/Supplements/supplement_2019_3.pdf [abstract]

0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 22 Aug 2020 No. 1818